The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Prevention of palmoplantar erythrodysesthesia (PPE) with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (PLD), a placebo-controlled, double blinded, phase lll trial (SAKK 92/08).
Thomas Ruhstaller
No relevant relationships to disclose
Karin Ribi
No relevant relationships to disclose
Hong Sun
No relevant relationships to disclose
Shu-Fang Schmitz
No relevant relationships to disclose
Markus Borner
No relevant relationships to disclose
Annette Winkler
No relevant relationships to disclose
Andreas Mueller
No relevant relationships to disclose
Lukas von Rohr
No relevant relationships to disclose
Ralph C. Winterhalder
No relevant relationships to disclose
Christoph Rochlitz
No relevant relationships to disclose
Roger Von Moos
No relevant relationships to disclose
Sandro Anchisi
No relevant relationships to disclose
Clemens B. Caspar
No relevant relationships to disclose
Khalil Zaman
No relevant relationships to disclose
Alexandre Bodmer
No relevant relationships to disclose
Michael Beyeler
No relevant relationships to disclose
Simona Berardi
No relevant relationships to disclose
Beat J. K. Thurlimann
No relevant relationships to disclose
Arnoud Templeton
No relevant relationships to disclose